RHÖN-KLINIKUM Aktiengesellschaft
ISIN: DE0007042301
WKN: 704230
07 August 2025 08:59AM

EQS-News: RHÖN-KLINIKUM AG closes first half of 2025 with solid results

RHÖN-KLINIKUM Aktiengesellschaft · ISIN: DE0007042301 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2180678

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Half Year Results/Miscellaneous
RHÖN-KLINIKUM AG closes first half of 2025 with solid results

07.08.2025 / 08:59 CET/CEST
The issuer is solely responsible for the content of this announcement.


Corporate News
Bad Neustadt a. d. Saale | 7 August 2025

RHÖN-KLINIKUM AG closes first half of 2025 with solid results

  • Revenues up by 7.5% driven by a moderate increase in patient numbers and key performance indicators
  • Solid and stable EBITDA development despite end to relief from the legislator for higher energy prices and challenges in cost structures
  • Consolidated profit of EUR 14.7 million with a decrease in finance result keeps equity ratio stable
  • Board of Management focused to manage the Group in a consistent, flexible and sustainable manner at times of a difficult financial and economic environment for hospitals in Germany

RHÖN-KLINIKUM AG closed the first half of 2025 once again with an increase in revenues of 7.5 % to EUR 883.5 million (H1 2024: EUR 775.5 million). From January to June 2025 a total of 471,295 patients were treated on an inpatient and outpatient basis in the Group’s hospitals and medical care centres, 1.8 % more compared with the same period of the previous year (H1 2024: 463,111). At EUR 46.7 million, EBITDA was below the previous year’s level (H1 2024: EUR 49.1 million). Consolidated profit decreased to EUR 14.7 million (H1 2024: EUR 20.6 million). The equity capital ratio stands at 71.3 % (FY 2024: 71.4 %).

Despite stable performance indicators, the expired entitlement to reimbursements by the legislator for higher energy expenditures recognised in the first half of 2024 in the amount of EUR 13 million as well as the declining trend in interest rates had an impact on consolidated profit. Moreover, the first six months of financial year 2025 continued to feel the implicit effects of geopolitical risks and the resulting high purchasing prices, and was impacted more directly by wage increases as well as policy developments associated with the hospital reform in Germany.

Dr. Stefan Stranz, member of the Board of Management of RHÖN-KLINIKUM AG: “Our Company’s economic performance continues to be robust, and can be considered positive in view of the demanding financial situation and trend of hospitals in the German hospital sector.”

Dr. Gunther K. Weiß, member of the Board of Management of RHÖN-KLINIKUM AG: “Our Company can hold its own economic position in an extremely challenging market environment. Therefore, we are looking at options to address the funding shortfall in the healthcare sector caused by the significant increase in operating and investing costs, and to continuously seek for synergies within our Group network.”


Outlook for 2025 confirmed

For the current financial year, the Group expects revenues of EUR 1.7 billion within a range of plus or minus 5 %. For earnings before interest, tax and depreciation/amortisation (EBITDA), a level of between EUR 110 million and EUR 125 million is expected. In addition to the financial numbers, RHÖN-KLINIKUM AG also takes account of the non-financial performance indicators of number of cases and cost weights in the management of the Company. This is expected to see a moderate increase compared with the previous year.

This forecast reflects the heightened regulatory interference by the German legislator and the political implementation of the necessary hospital reform.

The Group notes that the outlook is subject to considerable uncertainties in connection with the numerous global crises resulting among other things in higher prices and supply chain issues, as well as any further regulatory measures impacting the remuneration structure for medical services in 2025.

The 2025 Half-Year Financial Report is published on the Internet.

 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 913,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,700 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com


Contact:

RHÖN-KLINIKUM AG | Head of Group Finance 
Norman Dittes | T. +49 9771 65-12210 | norman.dittes@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Corporate Communications  
Heike Ochmann | T. +49 9771 65-12130 | heike.ochmann@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale



07.08.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 2180678

 
End of News EQS News Service

2180678  07.08.2025 CET/CEST

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2020 2021 2022 2023 2024 2025e 2026e
Sales1 1.360,16 1.402,01 1.446,09 1.463,98 1.595,62 1.700,00 0,00
EBITDA1,2 80,23 101,16 105,65 105,88 110,77 103,00 0,00
EBITDA-Margin3 5,90 7,22 7,31 7,23 6,94 6,06 0,00
EBIT1,4 10,60 30,52 36,11 40,40 48,15 42,00 0,00
EBIT-Margin5 0,78 2,18 2,50 2,76 3,02 2,47 0,00
Net Profit (Loss)1 2,46 30,23 26,94 40,17 45,21 38,00 0,00
Net-Margin6 0,18 2,16 1,86 2,74 2,83 2,24 0,00
Cashflow1,7 113,30 97,50 41,30 109,00 127,60 110,00 0,00
Earnings per share8 0,02 0,42 0,38 0,58 0,65 0,56 0,70
Dividend per share8 0,00 0,00 0,15 0,00 0,10 0,10 0,15
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Rhön-Klinikum
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
704230 DE0007042301 AG 883,91 Mio € 19.06.1991 Halten 9F2G86FM+GX
* * *
PE 2027e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
16,92 26,47 0,64 23,91 0,69 6,93 0,55
Dividends
Dividend '2023
in €
Dividend '2024
in €
Dividend '2025e
in €
Div.-Yield '2025e
in %
0,00 0,10 0,10 0,76%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
27.05.2026 07.05.2026 06.08.2026 05.11.2026 26.03.2026
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+0,76%
13,20 €
ATH 32,12 €
+4,97% +6,16% +3,94% -10,20% +428,00%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2026          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2026 by Gereon Kruse #BGFL